Lilly Withdraws India Patent Request For Already-Marketed Forteo (India)
This article was originally published in PharmAsia News
Eli Lilly withdrew a patent request in India for its new-generation biotech drug, Forteo (teriparatide recombinant human) in crystal form for treating osteoporosis. The U.S. company lost an earlier claim for a patent for the $600 million drug in another form when it faced opposition from USV. Lilly already had begun selling the drug in India as the only biotech drug for the disease, with the assumption it would soon have patent protection. USV and at least one other company are expected to launch generics as a result of the patent withdrawal. (Click here for more )
You may also be interested in...
Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
LifeSignals plans to soon launch a biosensor patch to consumers to help them monitor for potential symptoms of COVID-19.